Amessou M, Bortoli S, Liemans V, Collinet M, Desbuquois B, Brichard S, Girard J
Unité 30 INSERM, Centre Hospitalier Necker Enfants-Malades, Paris, France.
Eur J Endocrinol. 1999 Jan;140(1):79-86. doi: 10.1530/eje.0.1400079.
Administration of vanadate, an insulinomimetic agent, has been shown to normalize the increased number of insulin receptors in the liver of streptozotocin-induced diabetic rats. In the present study, the effects of vanadate on various steps of expression of the liver insulin receptor gene in diabetic rats have been analyzed and compared with those of phlorizin, a glucopenic drug devoid of insulinomimetic properties. Livers of rats killed 23 days after streptozotocin injection showed a 30-40% increase in the number of cell surface and intracellular insulin receptors, a 50-90% increase in the levels of 9.5 and 7.5 kb insulin receptor mRNA species, and a 20% decrease in the relative abundance of the A (exon 11-) insulin receptor mRNA isotype. Daily administration of vanadate or phlorizin from day 5 to day 23 prevented the increase in insulin receptor number and mRNA level, and vanadate treatment also normalized receptor mRNA isotype expression. Unlike observations in vivo, vanadate and phlorizin differentially affected the expression of the insulin receptor gene in Fao hepatoma cells. Vanadate treatment (0.5 mmol/l for 4 h) decreased the levels of the 9.5 and 7.5 kb insulin receptor transcripts by at least twofold, without affecting the relative abundance of the A insulin receptor mRNA isotype. In contrast, phlorizin treatment (5 mmol/l for 4 h) slightly increased or did not affect the levels of the 9.5 and 7.5 kb insulin receptor transcripts respectively, and increased by twofold the relative expression of the A insulin receptor mRNA isotype. It is suggested that, although mediated in part by a reversal of hyperglycemia, normalization of liver insulin receptor gene expression by vanadate treatment in diabetic rats may also involve a direct inhibitory effect of this drug on gene expression.
钒酸盐是一种胰岛素模拟剂,已证明其可使链脲佐菌素诱导的糖尿病大鼠肝脏中增加的胰岛素受体数量恢复正常。在本研究中,分析了钒酸盐对糖尿病大鼠肝脏胰岛素受体基因表达各个步骤的影响,并与缺乏胰岛素模拟特性的降血糖药物根皮苷的作用进行了比较。链脲佐菌素注射23天后处死的大鼠肝脏显示,细胞表面和细胞内胰岛素受体数量增加30 - 40%,9.5 kb和7.5 kb胰岛素受体mRNA种类水平增加50 - 90%,A(外显子11 -)胰岛素受体mRNA亚型的相对丰度降低20%。从第5天到第23天每日给予钒酸盐或根皮苷可阻止胰岛素受体数量和mRNA水平的增加,钒酸盐治疗还使受体mRNA亚型表达恢复正常。与体内观察结果不同,钒酸盐和根皮苷对Fao肝癌细胞中胰岛素受体基因的表达有不同影响。钒酸盐处理(0.5 mmol/l,处理4小时)使9.5 kb和7.5 kb胰岛素受体转录本水平至少降低两倍,而不影响A胰岛素受体mRNA亚型的相对丰度。相比之下,根皮苷处理(5 mmol/l,处理4小时)分别使9.5 kb和7.5 kb胰岛素受体转录本水平略有增加或无影响,并使A胰岛素受体mRNA亚型的相对表达增加两倍。研究表明,虽然部分是通过高血糖的逆转介导的,但钒酸盐治疗使糖尿病大鼠肝脏胰岛素受体基因表达正常化也可能涉及该药物对基因表达的直接抑制作用。